🩺 Biomedical Engineering Terminology Glossary: 55 Essential Terms Explained

Why These Terms Matter

Biomedical engineering sits at the intersection of mechanical, electrical, materials, and software engineering with human physiology and clinical practice — and its vocabulary reflects that mix. A biomedical engineer working on an implant must speak the language of fatigue analysis and metallurgy; the same engineer working on a patient monitor must understand electrical safety standards and biosignal processing; and nearly all of them must understand the regulatory vocabulary that determines whether a device can legally reach a patient. Getting these terms wrong is not just an academic problem — regulatory submissions, risk files, and design history records are built on precisely defined terminology, and a mismatch between what an engineer means and what a standard or regulator means can delay clearance or, worse, put patients at risk.

This glossary collects 55 of the most important terms a biomedical engineer, medical device developer, or clinical engineer encounters, spanning regulatory affairs, biomechanics, biomaterials, biosignals, and hospital equipment management. Terms are organized alphabetically with references to the governing standard or regulation where applicable.

A

Active Implantable Medical Device (AIMD) — EU MDR / IEC 60601-1

An implanted device that relies on a source of electrical or other energy (other than that generated directly by the body or gravity) to function — pacemakers, implantable cardioverter-defibrillators (ICDs), and neurostimulators are classic examples. AIMDs face additional regulatory scrutiny beyond passive implants because a malfunction can directly and immediately endanger the patient, and because the implanted battery and electronics must survive years inside the body without maintenance access.

Adverse Event — ISO 14971 / FDA MedWatch

Any untoward medical occurrence in a patient or user associated with the use of a medical device, whether or not it is considered device-related. Manufacturers are required to track, investigate, and in many cases report adverse events to regulators (via FDA's MDR pathway in the US or vigilance reporting under EU MDR). Adverse event data feeds directly back into the device's risk management file and post-market surveillance plan.

Ambulatory Monitoring — Clinical Engineering

Continuous physiological monitoring (ECG, blood pressure, glucose, etc.) of a patient who is mobile and not confined to a hospital bed, typically using wearable or portable devices such as Holter monitors or continuous glucose monitors (CGMs). Ambulatory devices must balance signal fidelity against battery life, motion artifact rejection, and wearability — constraints that don't apply to bedside monitors with unlimited power and a stationary patient.

Ampacity of Implant Leads — IEC 60601-2-27

Not a common term, but pacemaker and neurostimulator lead conductors must be sized to carry pacing/stimulation current without excessive impedance rise over the device's service life, since lead fracture or insulation failure is one of the leading causes of implant revision surgery. Lead reliability testing (flex-fatigue cycling to simulate years of cardiac motion) is a core part of AIMD verification.

Applied Part — IEC 60601-1

The part of a medical electrical device that, in normal use, necessarily comes into physical contact with the patient for the device to perform its function — an ECG electrode, a pulse oximeter probe, or an ultrasound transducer head. Applied parts are classified as Type B, BF, or CF depending on the degree of electrical isolation and defibrillation protection required, with CF (cardiac floating) applied parts — used in direct cardiac contact — requiring the highest leakage-current limits in the standard.

B

Biocompatibility — ISO 10993

The ability of a material to perform with an appropriate host response when used in a specific medical application — in plain terms, that a material won't provoke toxicity, inflammation, an immune reaction, or carcinogenicity when it contacts tissue or blood. Biocompatibility is not a single pass/fail property of a material in isolation; it depends on the contact duration (limited, prolonged, or permanent) and contact type (surface, external communicating, or implant) per the ISO 10993-1 evaluation matrix, which determines which battery of tests (cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation, hemocompatibility) applies.

Biomechanics — Biomedical Engineering

The application of mechanical engineering principles — statics, dynamics, stress analysis, materials science — to biological systems, most commonly the musculoskeletal system. Biomechanics underlies implant design (hip joint reaction forces, spinal fusion hardware loading), gait analysis, prosthetic and orthotic design, and injury biomechanics research.

Biosignal — Biomedical Instrumentation

Any measurable electrical, mechanical, or chemical signal produced by a biological process — ECG (cardiac electrical activity), EEG (brain electrical activity), EMG (muscle electrical activity), and photoplethysmography (blood volume changes used in pulse oximetry) are the most common. Biosignals are typically low amplitude (microvolts to millivolts) and heavily contaminated by noise, so amplification, filtering, and artifact rejection are central design problems in biosignal acquisition hardware.

Bioresorbable Material — Biomaterials

A material engineered to break down and be absorbed by the body over a defined timeframe after it has served its purpose, eliminating the need for a second surgery to remove it. Bioresorbable polymers (like PLLA or PLGA) are used in sutures, drug-eluting stent scaffolds, and some orthopedic fixation devices; the degradation rate must be tuned so mechanical support persists exactly as long as the tissue needs it, no longer.

Bland-Altman Analysis — Clinical Validation Statistics

A statistical method for comparing agreement between two measurement techniques (for example, a new non-invasive blood pressure device against an invasive arterial line reference), plotting the difference between paired measurements against their mean to visualize bias and limits of agreement. It's the standard method regulators expect for validating a new physiological measurement device against a clinical gold standard, and is very different from correlation analysis, which can look excellent even when two methods disagree substantially in absolute terms.

C

Class I / II / III Device — FDA 21 CFR 860

The FDA's risk-based classification system for medical devices in the United States. Class I devices (tongue depressors, bandages) pose minimal risk and are subject to general controls only; Class II devices (infusion pumps, most diagnostic equipment) pose moderate risk and typically require 510(k) premarket notification demonstrating substantial equivalence to a predicate device; Class III devices (pacemakers, heart valves) support or sustain life or pose significant risk and generally require the more rigorous Premarket Approval (PMA) pathway with clinical data.

Clinical Engineering — Healthcare Technology Management

The engineering discipline responsible for managing the medical equipment lifecycle inside a healthcare facility — procurement, incoming inspection, preventive maintenance, safety testing, recall management, and eventual decommissioning of devices already in clinical use. Clinical engineers are distinct from device manufacturers' R&D engineers; their job is keeping thousands of in-service devices safe and functional across an entire hospital system, often under standards like the Joint Commission's Environment of Care requirements.

Corrective and Preventive Action (CAPA) — ISO 13485 / 21 CFR 820

A formal quality system process for investigating the root cause of a nonconformance or complaint, implementing a fix, and verifying the fix's effectiveness, plus taking preventive steps against recurrence. CAPA is one of the most heavily audited elements of a medical device quality management system because a weak CAPA process is a strong predictor that other quality problems will go uncorrected.

Cybersecurity (Medical Device) — FDA Premarket Cybersecurity Guidance / IEC 81001-5-1

The set of design controls, risk assessments (SBOM — software bill of materials), and lifecycle processes that protect a networked medical device from unauthorized access or manipulation that could compromise patient safety or data. Since 2023, FDA has statutory authority to refuse to accept submissions for internet-connected devices that lack an adequate cybersecurity plan, making this a mandatory (not optional) part of device development for anything with connectivity.

Cytotoxicity Testing — ISO 10993-5

An in vitro test exposing cultured mammalian cells to a material extract or direct contact to determine whether the material releases substances toxic enough to kill or damage the cells. Cytotoxicity is typically the first and least expensive biocompatibility test run on a new material, and a cytotoxic result generally halts further development of that material formulation before more expensive animal or clinical testing is attempted.

D

Design History File (DHF) — 21 CFR 820.30 / ISO 13485

The compiled record documenting the design and development history of a finished medical device — design inputs, design outputs, verification and validation results, design reviews, and design changes — assembled to demonstrate the design was developed in accordance with the approved design plan. An FDA inspector's first request during an audit is almost always the DHF, because it is the single artifact that proves the design controls process was actually followed rather than just documented on paper.

Design Input / Design Output — 21 CFR 820.30

Design inputs are the physical and performance requirements a device must meet (defined before design begins); design outputs are the results of the design effort — drawings, specifications, source code — that must be traceable back to and verifiable against the design inputs. The input-output-verification chain is the backbone of design controls, and a broken traceability link (an output with no corresponding input, or vice versa) is one of the most common FDA 483 observations.

Design Validation vs. Design Verification — 21 CFR 820.30(f)/(g)

Verification confirms the device meets its specified design inputs ("did we build the device right?" — typically bench testing against a spec). Validation confirms the device meets user needs and intended uses in the actual or simulated use environment ("did we build the right device?" — typically usability studies or clinical evaluation). A device can pass every verification test and still fail validation if the specifications themselves didn't capture what clinicians actually needed.

Drug-Eluting Device — Combination Products

A medical device that releases a pharmaceutical agent over time, such as a drug-eluting coronary stent that releases an anti-proliferative drug to prevent restenosis (renarrowing) of the vessel. These combination products are regulated under both device and drug frameworks simultaneously, and the coating's release kinetics (how fast the drug elutes) is as critical a design parameter as the stent's mechanical expansion force.

Duty Cycle (Therapeutic Device) — IEC 60601

The proportion of time a device actively delivers energy or therapy versus rests, expressed as a percentage or ratio — relevant for devices like electrosurgical units, therapeutic ultrasound, or neurostimulators where continuous full-power operation would cause thermal tissue damage. Duty cycle limits are a primary thermal-safety design control distinct from the raw power output rating.

E

Electrocardiogram (ECG/EKG) — Biosignal Acquisition

A recording of the heart's electrical activity captured via skin electrodes, showing the characteristic P-QRS-T waveform corresponding to atrial depolarization, ventricular depolarization, and ventricular repolarization respectively. ECG amplifier design must reject a common-mode 50/60 Hz mains interference signal thousands of times larger than the millivolt-level cardiac signal itself, which is why ECG front-ends rely heavily on instrumentation amplifiers with very high common-mode rejection ratio (CMRR).

Electrode-Tissue Impedance — Bioinstrumentation

The electrical impedance at the interface between a skin or implanted electrode and the underlying tissue, which varies with electrode material, contact area, skin preparation, and time (impedance typically drops as gel hydrates the skin). High or unstable electrode impedance degrades signal quality and is a common source of motion artifact in ambulatory ECG and EEG recordings.

Electromagnetic Compatibility (EMC) — IEC 60601-1-2

A device's ability to function correctly in its intended electromagnetic environment without emitting interference that disrupts other equipment, and without being disrupted by interference from other sources (including cell phones, RFID, electrosurgical units, and MRI fields for devices used near an MRI suite). EMC testing for medical devices is more stringent than for consumer electronics because a monitor that glitches from a nearby cell phone can directly endanger a patient.

Electromyography (EMG) — Biosignal Acquisition

Recording of the electrical activity generated by skeletal muscle contraction, captured via surface electrodes (sEMG) or fine-wire/needle electrodes inserted into the muscle. EMG signals drive myoelectric prosthetic control (a below-elbow prosthetic hand interpreting residual forearm muscle signals to control grip) and are used diagnostically to assess neuromuscular disorders.

Essential Performance — IEC 60601-1

Performance necessary to achieve freedom from unacceptable risk, as distinct from performance related to convenience or accuracy that isn't safety-critical. Identifying which functions of a device constitute "essential performance" is a required step in the risk management process, because those functions get subjected to more rigorous testing (including under single-fault conditions) than non-essential features.

F

Fatigue Strength (Implant) — ASTM F1801 / ISO 14801

The maximum cyclic stress an implant or implant component can withstand for a specified number of load cycles (often 5–10 million, simulating years of gait or chewing cycles) without failing. Fatigue strength, not ultimate tensile strength, governs orthopedic and dental implant design because implants experience millions of repetitive loading cycles over a service life measured in years, and materials that fatigue-crack well below their static strength (a phenomenon well understood in titanium and cobalt-chrome alloys) can fail suddenly after years of apparently successful service.

Fault Tree Analysis (FTA) — ISO 14971 supporting tool

A top-down deductive risk analysis technique starting from an undesired top event (e.g., "device delivers overdose") and working backward through logic gates to identify the combinations of component failures that could cause it. FTA complements FMEA (which works bottom-up from individual component failure modes) and is especially useful for identifying dangerous failure combinations that single-point FMEA analysis might miss.

Finite Element Analysis (FEA) for Implants — Biomechanics

Computational stress/strain modeling used to predict how an implant (a hip stem, spinal rod, or dental implant) will perform under physiological loading before physical prototypes are built and tested, and to identify stress concentration locations likely to initiate fatigue cracks. FEA results feed into but do not replace physical fatigue testing, since regulators require empirical verification of computational predictions.

510(k) Premarket Notification — FDA 21 CFR 807

The FDA regulatory pathway for most Class II devices, in which the manufacturer demonstrates the new device is "substantially equivalent" to an already-legally-marketed predicate device in intended use and technological characteristics, rather than proving safety and effectiveness from scratch. The predicate device comparison — and justifying why any technological differences don't raise new questions of safety or effectiveness — is the central argument of a 510(k) submission.

G

Gait Analysis — Biomechanics

The systematic measurement and analysis of human walking, using motion capture, force plates, and EMG to quantify joint angles, ground reaction forces, and muscle activation timing throughout the gait cycle. Gait analysis informs prosthetic and orthotic alignment, surgical planning for gait-affecting conditions like cerebral palsy, and post-operative outcome assessment for joint replacements.

Genotoxicity — ISO 10993-3

The potential of a material or its degradation products to damage genetic material (DNA) within cells, which could lead to mutations or cancer. Genotoxicity is part of the standard biocompatibility test battery for any material with prolonged or permanent tissue contact, tested via assays like the Ames test (bacterial reverse mutation) and the mouse lymphoma assay.

Ground Fault Current (Patient Circuit) — IEC 60601-1

Leakage current that would flow to ground through a patient or applied part if the protective earth connection were to fail — a key parameter limited by IEC 60601-1's leakage current tables, since a patient connected to a device's applied part (an ECG lead, for instance) can become an unintended path to ground if isolation fails.

H

Hemocompatibility — ISO 10993-4

The property of a material that contacts blood not to cause clot formation (thrombosis), hemolysis (red blood cell rupture), complement activation, or other adverse blood interactions. Hemocompatibility testing is required for any device with blood contact — catheters, stents, dialysis circuits, oxygenator membranes — and is one of the more difficult biocompatibility categories to pass because almost any foreign surface triggers some degree of the blood coagulation cascade.

Human Factors Engineering (HFE) / Usability Engineering — IEC 62366-1 / FDA Human Factors Guidance

The discipline of designing medical devices to minimize use error by accounting for how real users (clinicians, patients, caregivers) actually interact with the device under realistic conditions, including stress, poor lighting, and unfamiliar environments. FDA requires a formative and summative human factors validation study for many devices, particularly those with a history of use-error-related adverse events like infusion pumps and insulin injectors.

Hydroxyapatite (HA) Coating — Orthopedic Biomaterials

A calcium-phosphate ceramic coating applied to the surface of orthopedic implants (hip and knee stems) that closely mimics the mineral composition of natural bone, promoting osseointegration — direct bony ingrowth onto the implant surface without an intervening fibrous tissue layer. HA-coated implants are designed for cementless (press-fit) fixation, relying on bone growth rather than bone cement for long-term stability.

I

IEC 60601-1 — Medical Electrical Equipment Safety Standard

The foundational international standard for the basic safety and essential performance of medical electrical equipment, covering electrical shock hazards, mechanical hazards, thermal hazards, and radiation hazards. Nearly every powered medical device sold internationally must comply with 60601-1 and its relevant "collateral" (60601-1-x, general requirements like EMC or alarms) and "particular" (60601-2-x, device-specific) standards.

Implantable Pulse Generator (IPG) — Active Implants

The battery-powered electronics module of an active implantable device — the "can" of a pacemaker, ICD, or spinal cord stimulator — that generates the electrical pulses delivered through leads to the target tissue. IPG design must fit a hermetically sealed, biocompatible titanium enclosure with years of battery life into a volume small enough for subcutaneous implantation.

Investigational Device Exemption (IDE) — FDA 21 CFR 812

FDA authorization allowing a significant-risk investigational device to be used in a clinical study to collect safety and effectiveness data needed to support a future PMA or 510(k) submission, without the device yet being approved for general commercial distribution. An approved IDE is the gate that must be passed before enrolling US patients in most Class III device clinical trials.

Ischemia — Clinical Physiology (relevant to device design)

A restriction in blood supply to tissue causing a shortage of oxygen needed for cellular metabolism — a condition that many biomedical devices are designed to detect (ECG ST-segment monitoring for cardiac ischemia) or treat (thrombectomy devices, stents) or avoid causing (tourniquet time limits, cuff pressure limits on blood pressure devices).

ISO 13485 — Medical Device Quality Management Systems

The international standard specifying requirements for a quality management system where an organization needs to demonstrate its ability to consistently provide medical devices that meet customer and regulatory requirements. ISO 13485 certification is effectively a prerequisite for selling medical devices in most global markets and forms the backbone of a manufacturer's design controls, CAPA, complaint handling, and supplier management processes.

ISO 14971 — Application of Risk Management to Medical Devices

The international standard defining the risk management process a manufacturer must apply throughout a device's lifecycle: risk analysis, risk evaluation, risk control, and production/post-production monitoring. Every hazard identified must be traced through a risk control measure and residual risk must be evaluated as acceptable — the resulting risk management file is one of the most scrutinized documents in any regulatory submission.

L

Leakage Current — IEC 60601-1

Unintended current that flows from a device's electrical parts to ground, to the enclosure, or to the patient through paths other than the intended circuit — categorized as earth leakage, enclosure leakage, and patient leakage current, each with distinct allowable limits under normal and single-fault conditions. Leakage current limits are dramatically tighter for applied parts with direct cardiac contact (Type CF) than for parts that merely touch skin (Type B), reflecting the far greater danger of even microamp-level currents reaching the heart directly.

Loss of Fixation — Orthopedic Implants

Failure of an implant to remain mechanically stable relative to the bone it is attached to — through screw loosening, cement mantle fracture, or failure of bony ingrowth — a leading cause of orthopedic implant revision surgery distinct from fatigue fracture of the implant material itself.

M

Maximum Permissible Exposure (MPE) — Medical Imaging / Laser Safety

The highest level of a physical agent (ionizing radiation dose, laser energy, ultrasound intensity) to which tissue can be exposed without unacceptable risk of injury, as defined by standards bodies like the IEC or ANSI Z136. Diagnostic imaging equipment design (CT dose modulation, ultrasound acoustic output limits) is built around staying safely under the relevant MPE while still producing diagnostically useful images.

Medical Device Reporting (MDR) — 21 CFR 803

The FDA regulation requiring manufacturers, importers, and device user facilities to report deaths, serious injuries, and certain malfunctions associated with medical devices within specified timeframes. MDR data is aggregated in FDA's public MAUDE database and is a primary input to post-market surveillance and eventual recall decisions.

MRI Conditional / Compatible Labeling — ASTM F2503

A labeling designation (MR Safe, MR Conditional, or MR Unsafe) indicating whether a device — particularly an implant — poses a known hazard in the MRI environment, and under what specific conditions (field strength, gradient limits, RF power) an MR Conditional device can be safely scanned. This matters enormously for implant design because the strong static magnetic field, switching gradients, and RF energy of an MRI can heat, move, or malfunction ferromagnetic or electronic implants.

Myoelectric Control — Prosthetics

Control of a powered prosthetic limb using EMG signals detected from the residual limb's remaining muscles, translated by onboard electronics into motor commands for grip or joint movement. Pattern-recognition myoelectric control (interpreting complex multi-muscle activation patterns rather than simple on/off signals) is an active area of prosthetics research aiming for more natural, intuitive limb control.

O

Osseointegration — Orthopedic & Dental Implants

The direct structural and functional connection formed between living bone and the surface of a load-bearing implant, without an intervening layer of soft fibrous tissue — first characterized in dental implant research and now central to cementless orthopedic implant design. Implant surface texture (porous coatings, grit-blasting, HA coating) is engineered specifically to promote osseointegration over the weeks following surgery.

Overall Length Sensitivity (Pulse Oximetry) — Not applicable — see Photoplethysmography

(Cross-reference note: pulse oximetry terminology is covered under Photoplethysmography and SpO2 below.)

P

Photoplethysmography (PPG) — Optical Biosensing

An optical technique that measures changes in blood volume in the microvascular tissue bed by detecting variations in light absorption or reflection, most commonly used in pulse oximeters (clipped on a fingertip) and wearable heart-rate sensors. PPG signal quality is highly sensitive to motion artifact, skin pigmentation, and peripheral perfusion — all active challenge areas for wearable device manufacturers.

Pixel Pitch / Spatial Resolution (Medical Imaging) — DICOM / Medical Imaging

The physical size represented by each pixel in a medical image, which together with detector characteristics determines the smallest anatomical feature the imaging system can resolve. Spatial resolution requirements differ dramatically by modality and clinical use — mammography demands sub-millimeter resolution to detect microcalcifications, while a bedside ultrasound for line placement has much looser requirements.

Post-Market Surveillance (PMS) — EU MDR / FDA 21 CFR 822

The ongoing, proactive collection and analysis of real-world data about a device's performance and safety after it has entered the market, feeding back into the risk management file and potentially triggering corrective actions, labeling changes, or recalls. EU MDR substantially strengthened PMS requirements compared to the prior Medical Device Directive, requiring manufacturers to maintain a formal PMS plan and periodic safety update reports for higher-risk devices.

Premarket Approval (PMA) — FDA 21 CFR 814

The most stringent FDA device approval pathway, required for most Class III devices, requiring the manufacturer to submit valid scientific evidence — typically including clinical trial data — demonstrating reasonable assurance of safety and effectiveness, reviewed and approved directly by FDA rather than cleared via predicate comparison. PMA review is far more resource-intensive and time-consuming than 510(k) clearance, reflecting the higher risk profile of the devices it covers.

Prosthesis / Orthosis — Rehabilitation Engineering

A prosthesis replaces a missing body part (a below-knee prosthetic leg); an orthosis supports, aligns, or corrects the function of an existing body part (an ankle-foot orthosis for foot drop). The distinction matters for design goals — a prosthesis must replicate lost function from scratch, while an orthosis must work in concert with the body part it supports.

Q

Quality System Regulation (QSR) / Quality Management System (QMS) — 21 CFR 820 (harmonizing toward ISO 13485)

The FDA's regulatory framework (historically distinct from, and as of 2024 harmonized with, ISO 13485) establishing the requirements for a manufacturer's design controls, document controls, corrective and preventive actions, and production process controls. Passing a QSR/QMS inspection is a prerequisite for continued legal marketing of a device in the US regardless of how the original clearance or approval was obtained.

R

Recall (Medical Device) — FDA 21 CFR 806

Correction or removal of a device already on the market to address a violation of law or a risk to health, classified by FDA as Class I (reasonable probability of serious injury or death), Class II (temporary or reversible harm), or Class III (unlikely to cause adverse health consequences). Note the classification numbering is independent from — and easily confused with — the device risk classification (Class I/II/III devices) described earlier in this glossary; a Class I device can still be subject to a Class I recall.

Reprocessing (Reusable Devices) — FDA Reprocessing Guidance / AAMI ST91

The validated process (cleaning, disinfection, and/or sterilization) applied to a reusable medical device between patient uses to render it safe for reuse, with the manufacturer required to provide validated reprocessing instructions and demonstrate the device can withstand the specified number of reprocessing cycles without degrading performance or safety.

Residual Risk — ISO 14971

The risk remaining after risk control measures have been implemented, which must be judged acceptable (against a pre-defined risk acceptability criteria) before a device can be released, with any residual risk disclosed in labeling if necessary for informed clinical decision-making. A risk management file is not considered complete until every identified hazard has documented residual risk acceptability, including an overall residual risk evaluation weighing benefits against the sum of all residual risks.

Risk Priority Number (RPN) — FMEA Methodology

In a Failure Mode and Effects Analysis, the product of severity, occurrence, and detectability ratings (each typically scored 1–10) used to rank failure modes by overall risk and prioritize which ones need design mitigation first. RPN is a widely used but imperfect prioritization tool — regulators increasingly expect severity to be evaluated independently as a hard gate (a catastrophic-severity failure mode may require mitigation regardless of a low RPN driven by rare occurrence).

S

Sensitization — ISO 10993-10

An allergic (immune-mediated) response that can develop after repeated or prolonged exposure to a material or its leachable chemicals, distinct from irritation, which is a direct non-immune inflammatory reaction. Sensitization testing (commonly the guinea pig maximization test or local lymph node assay) is part of the standard biocompatibility battery for materials with skin or mucosal contact.

Single Fault Condition — IEC 60601-1

A condition in which a single means for reducing risk (one protective measure) has failed, or a single abnormal condition is present — the standard's basic safety framework requires devices to remain safe (though not necessarily fully functional) under any single fault condition, reflecting the principle that no single component failure should endanger the patient.

Sterility Assurance Level (SAL) — ISO 11135 / ISO 11137

The probability of a single viable microorganism being present on a sterilized item after the sterilization process, expressed as a negative power of ten — a SAL of 10⁻⁶ (the standard requirement for devices contacting sterile tissue or the bloodstream) means a one-in-a-million chance of a surviving organism. SAL is a statistical measure, not a guarantee of absolute sterility, and sterilization process validation must demonstrate the chosen cycle reliably achieves the target SAL.

Sterilization Validation — ISO 11135 (EtO) / ISO 11137 (radiation) / ISO 17665 (moist heat)

The documented process of establishing, through physical and biological testing, that a chosen sterilization method and cycle parameters will consistently achieve the required sterility assurance level for a specific product and packaging configuration. Validation must be repeated whenever the product, packaging, or sterilization cycle changes significantly, and different methods (ethylene oxide, gamma/e-beam radiation, steam) each have distinct material compatibility and residual-toxin considerations.

Stress Shielding — Orthopedic Biomechanics

Bone resorption (loss of bone density) that occurs around a rigid implant because the implant, being much stiffer than bone, carries a disproportionate share of the mechanical load, reducing the mechanical stimulus (per Wolff's Law) that bone needs to maintain its density. Stress shielding is a key driver behind the push toward lower-modulus implant materials and designs that more closely match the stiffness of natural bone, since excessive stress shielding can loosen an implant over time.

Substantial Equivalence — FDA 510(k) Pathway

The regulatory standard a new device must meet under the 510(k) pathway — having the same intended use as a legally marketed predicate device, and either the same technological characteristics or different characteristics that don't raise new questions of safety or effectiveness (typically supported by performance testing). Establishing substantial equivalence, not proving independent safety and effectiveness from scratch, is the core burden of a 510(k) submission.

T

Telemetry (Patient Monitoring) — Clinical Engineering

Wireless transmission of physiological data (typically ECG) from an ambulatory patient-worn transmitter to a central monitoring station, allowing patients to move around a unit while remaining continuously monitored. Hospital telemetry systems must manage RF spectrum allocation carefully across dozens of simultaneously transmitting patient units to avoid interference and dropped signals.

Thrombogenicity — Hemocompatibility (see also Hemocompatibility)

The tendency of a blood-contacting material's surface to trigger clot (thrombus) formation, driven by protein adsorption and platelet activation at the material interface. Reducing thrombogenicity — through surface coatings, heparin bonding, or surface texture optimization — is a central design challenge for catheters, stents, and extracorporeal circuits like dialysis or ECMO.

Traceability Matrix — Design Controls

A document linking each design input requirement through its corresponding design output, verification test, and validation activity, used to demonstrate — and for an auditor to quickly confirm — that every requirement was actually implemented and tested, and that no verification or validation activity exists without a corresponding requirement driving it.

U

Usability Engineering File — IEC 62366-1

The compiled documentation of the human factors/usability engineering process applied to a device — use specification, use-related risk analysis, formative evaluations, and the final summative (validation) usability study — analogous in structure and audit importance to the Design History File but focused specifically on use-related risk.

Use Error — IEC 62366-1

An act or omission by a device user that produces a result different from that intended by the manufacturer and by the user — distinguished from a "use mistake" involving a deliberate but flawed strategy, and from a device malfunction, since a use error can occur even when the device performs exactly as designed. Distinguishing genuine use error (a design or labeling problem to be fixed) from simple user negligence is a central and often contentious part of adverse-event root-cause investigation.

V

Validation (Process) — 21 CFR 820.75 / General Quality Systems Term

Establishing, by objective evidence, that a manufacturing process consistently produces a result meeting predetermined specifications — required whenever the output of a process cannot be fully verified by subsequent inspection or test alone (sterilization is the classic example, since you cannot non-destructively test every unit for sterility). Process validation (installation qualification, operational qualification, performance qualification — IQ/OQ/PQ) is distinct from design validation described earlier.

Vigilance Reporting — EU MDR

The EU regulatory equivalent of FDA's Medical Device Reporting system, requiring manufacturers to report serious incidents and field safety corrective actions to the relevant competent authority and, under EU MDR, into the EUDAMED database, feeding the region's post-market surveillance system.

W

Wear Debris — Orthopedic Implants

Microscopic particles generated at articulating implant surfaces (a hip or knee joint bearing surface) through mechanical wear over years of use, which can trigger an inflammatory foreign-body response in surrounding tissue (osteolysis) that loosens the implant even when the implant itself has not fractured. Wear debris generation rate — driven by bearing material choice (metal-on-polyethylene, ceramic-on-ceramic, etc.) — is a key long-term implant survivorship factor distinct from acute fatigue failure.

Wolff's Law — Bone Biomechanics

The principle, observed by 19th-century anatomist Julius Wolff, that living bone remodels itself over time in response to the mechanical loads placed on it — bone under higher habitual stress becomes denser and stronger, while bone shielded from normal stress (as in stress shielding around a rigid implant) loses density. Wolff's Law is the biological mechanism underlying stress-shielding concerns in implant design and the rationale for weight-bearing exercise in bone health.